MAPT and Alzheimer disease: On the other hand, studies on animal model of AD (e.g., APP/PS1 mice) have shown that HupA could suppress Aβ accumulation, and amyloid plaques and hyperphosphorylated tau formation when drug administration began at an early stage (Wang et al., 2011; Huang et al., 2014).